Mucin antibodies - new tools in diagnosis and therapy of cancer.

U. A. Wittel, A. Goel, G. C. Varshney, Surinder Kumar Batra

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Many cancer and diseased cells are distinguished from their normal counterparts by an altered expression of cell-surface epitopes. One family of molecules that show altered expression on tumor cells is mucins (MUC). Unlike normal tissue where MUC exists as heavily glycosylated form, the disease- or tumor-associated MUC molecules are underglycosylated. Such underglycosylation of the core protein in cancer tissues exposes new epitopes on the cell surface that are unique to cancer tissues. Several monoclonal antibodies (Mabs) have been generated against these normal and tumor-associated mucins. Enzymatic fragments of Mabs like F(ab')2 and Fab have shown improved clinical utility for diagnosis, imaging, and therapy of cancer. Genetic-engineering methods have been used to design antibody fragments exhibiting high functional affinity, good tumor localization, and rapid clearance from the blood stream thus minimizing radiation exposure to the normal tissues. Such recombinant fragments have shown encouraging results in preclinical studies using xenografted tumor bearing mice and present a whole new avenue for radioimmunotherapy and diagnosis of cancer.

Original languageEnglish (US)
JournalFrontiers in bioscience : a journal and virtual library
Volume6
StatePublished - Jan 1 2001

Fingerprint

Mucins
Tumors
Antibodies
Tissue
Neoplasms
Epitopes
Bearings (structural)
Monoclonal Antibodies
Cells
Therapeutics
Genetic engineering
Immunoglobulin Fragments
Molecules
Blood
Radioimmunotherapy
Imaging techniques
Radiation
Genetic Engineering
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Mucin antibodies - new tools in diagnosis and therapy of cancer. / Wittel, U. A.; Goel, A.; Varshney, G. C.; Batra, Surinder Kumar.

In: Frontiers in bioscience : a journal and virtual library, Vol. 6, 01.01.2001.

Research output: Contribution to journalReview article

@article{9fe666867a4947adbf62ac82274a8eeb,
title = "Mucin antibodies - new tools in diagnosis and therapy of cancer.",
abstract = "Many cancer and diseased cells are distinguished from their normal counterparts by an altered expression of cell-surface epitopes. One family of molecules that show altered expression on tumor cells is mucins (MUC). Unlike normal tissue where MUC exists as heavily glycosylated form, the disease- or tumor-associated MUC molecules are underglycosylated. Such underglycosylation of the core protein in cancer tissues exposes new epitopes on the cell surface that are unique to cancer tissues. Several monoclonal antibodies (Mabs) have been generated against these normal and tumor-associated mucins. Enzymatic fragments of Mabs like F(ab')2 and Fab have shown improved clinical utility for diagnosis, imaging, and therapy of cancer. Genetic-engineering methods have been used to design antibody fragments exhibiting high functional affinity, good tumor localization, and rapid clearance from the blood stream thus minimizing radiation exposure to the normal tissues. Such recombinant fragments have shown encouraging results in preclinical studies using xenografted tumor bearing mice and present a whole new avenue for radioimmunotherapy and diagnosis of cancer.",
author = "Wittel, {U. A.} and A. Goel and Varshney, {G. C.} and Batra, {Surinder Kumar}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Mucin antibodies - new tools in diagnosis and therapy of cancer.

AU - Wittel, U. A.

AU - Goel, A.

AU - Varshney, G. C.

AU - Batra, Surinder Kumar

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Many cancer and diseased cells are distinguished from their normal counterparts by an altered expression of cell-surface epitopes. One family of molecules that show altered expression on tumor cells is mucins (MUC). Unlike normal tissue where MUC exists as heavily glycosylated form, the disease- or tumor-associated MUC molecules are underglycosylated. Such underglycosylation of the core protein in cancer tissues exposes new epitopes on the cell surface that are unique to cancer tissues. Several monoclonal antibodies (Mabs) have been generated against these normal and tumor-associated mucins. Enzymatic fragments of Mabs like F(ab')2 and Fab have shown improved clinical utility for diagnosis, imaging, and therapy of cancer. Genetic-engineering methods have been used to design antibody fragments exhibiting high functional affinity, good tumor localization, and rapid clearance from the blood stream thus minimizing radiation exposure to the normal tissues. Such recombinant fragments have shown encouraging results in preclinical studies using xenografted tumor bearing mice and present a whole new avenue for radioimmunotherapy and diagnosis of cancer.

AB - Many cancer and diseased cells are distinguished from their normal counterparts by an altered expression of cell-surface epitopes. One family of molecules that show altered expression on tumor cells is mucins (MUC). Unlike normal tissue where MUC exists as heavily glycosylated form, the disease- or tumor-associated MUC molecules are underglycosylated. Such underglycosylation of the core protein in cancer tissues exposes new epitopes on the cell surface that are unique to cancer tissues. Several monoclonal antibodies (Mabs) have been generated against these normal and tumor-associated mucins. Enzymatic fragments of Mabs like F(ab')2 and Fab have shown improved clinical utility for diagnosis, imaging, and therapy of cancer. Genetic-engineering methods have been used to design antibody fragments exhibiting high functional affinity, good tumor localization, and rapid clearance from the blood stream thus minimizing radiation exposure to the normal tissues. Such recombinant fragments have shown encouraging results in preclinical studies using xenografted tumor bearing mice and present a whole new avenue for radioimmunotherapy and diagnosis of cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035488795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035488795&partnerID=8YFLogxK

M3 - Review article

VL - 6

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -